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Abstract
Background: To evaluate the evidence behind claims that Chinese Herbal Medicine,
specifically “three medicines and three formulations” (3M3F, comprising Jinhua
Qinggan, Lianhua Qingwen, Xuebijing, Qingfei Paidu, Huashi Baidu, and Xuanfei
Baidu), is an effective treatment for COVID-19.
Methods: We searched PubMed, MEDLINE and CNKI databases, preprint servers,
clinical trial registries and supplementary sources for Chinese- or English-language
randomized trials or non-randomized studies with comparator groups, which tested
the constituents of 3M3F in the treatment of COVID-19 up to September 2020.
Primary outcome was change in disease severity. Secondary outcomes included
various symptoms. Meta-analysis (using generic inverse variance random effects model)
was performed when there were two or more studies reporting on the same symptom.
Results: Of 607 articles identified, 13 primary studies (6 RCTs and 7 retrospective
non-randomized comparative studies) with 1467 participants met our final inclusion
criteria. Studies were small and had significant methodological limitations, most nota-
bly potential bias in assessment of outcomes. No study convincingly demonstrated a
statistically significant impact on change in disease severity. Eight studies reported
sufficiently similar secondary outcomes to be included in a meta-analysis. Some
statistically significant impacts on symptoms, chest CT manifestations, laboratory
variables and length of stay were demonstrated, but such findings were sparse and
many remain unreplicated.
Abbreviations: 3M3F, three medicines and three formulations; AE, adverse event; CDC, Centers for Disease Control and Prevention; CHM, Chinese herbal medicine; CI, confidence interval;
CNKI, China National Knowledge Infrastructure; COVID, Corona virus disease; CT, computerized tomography; HSBD, Huashi Baidu; JHQG, Jinhua Qinggan granule; LHQW, Lianhua Qingwen;
MD, mean difference; PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analyses; QFPD, Qingfei Paidu; RCT, randomized controlled trial; RoB, risk of bias; RR, risk ratio;
SMD, standardized mean differences; TCM, Traditional Chinese medicine; WHO, World Health Organization; XBJ, Xuebijing; XFBD, XuanFei Baidu.
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Conclusions: These findings neither support nor refute the claim that 3M3F alters
the severity of COVID-19 or alleviates symptoms. More rigorous studies are required
to properly ascertain the potential role of Chinese Herbal Medicine in COVID-19.
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1 | INTRODUCTION
China was the first country to be seriously affected by COVID-19.
The first version of the Novel Coronavirus Pneumonia Treatment Plan
was published on 16th January 2020,1 and the Plan was soon revised
into the seventh edition.2 From the fourth revision, the Plan included
Chinese herbal medicine (CHM) and recommended CHM to be effec-
tive to patients with all stages of disease from observation period to
critical phase.3,4 Six CHM recipes, known as the “3 Medicines and
3 Formulations” (3M3F, [三药三方]), were selected for use.
The “3 Medicines” (Jinhua Qinggan granule-JHQG, Lianhua
Qingwen-LHQW capsule/granule, Xuebijing-XBJ) are repurposed exis-
ting medicines, used for symptomatic relief of respiratory illnesses
including SARS, H1N1 influenza and pneumonia5-7 . The “3 Formula-
tions” (Lung Cleansing and Detoxifying Decoction, Qingfei Paidu-
QFPD decoction, Huashi Baidu-HSBD formula and XuanFei Baidu-XFBD
granule) are novel preparations, developed from existing CHM formu-
las for treatment of COVID-19.
The 3M3F were claimed to have significant efficacy after obser-
vation of population data, and the role of 3M3F in COVID-19 treat-
ment was officially announced in a Chinese government press
conference on 23 March 2020, with promotion as being able to
relieve symptoms, and reduce the number of mild of moderate cases
progressing to severe cases.8 Specific claims included that the com-
pound significantly improves immunological indicators for both mild
and severe COVID-19; that one of the Medicines (LHQW) and the
three formulations are effective in improving radiologically-assessed
lung infiltrates; that one of the formulations (XFBD) improves lympho-
cyte count by 17% and cure rate by 22%; and that another of the for-
mulations (HSBD) reduces the time for viral testing to turn negative
and shortens hospital stay by 3 days. One Medicine (LHQW) was
suggested to have antiviral and anti-inflammatory effects by inhibiting
the SARS-COV-2 replication and reducing the pro-inflammatory cyto-
kines production at the mRNA levels.9 These claims were widely
reported in the Chinese press and also in Chinese researchers' com-
munication to the WHO that the traditional and complementary medi-
cine unit of the WHO highly appraised the role of 3M3F.10
Due to the concise nature of the official statement, the above
findings were communicated in concise language with little detail of
data supporting claims. However, despite the paucity of available
data, 3M3F was readily and significantly implemented into COVID-19
treatment management. The South China Morning Post reported that
over 90% of Chinese COVID-19 patients had been treated with
CHM.11 Large quantities of 3M3F were shipped as part of the
Chinese government's aid package to other countries such as Italy,
Iran and Iraq.12,13 Despite unclear evidence of efficacy and some nega-
tive press in the West,14 they have been distributed by local civic orga-
nizations such as the Red Cross and Chinese embassies.15 These
organizations were taking the lead because regulations limit the official
inclusion of 3M3F in many settings outside of China. Nevertheless, the
Chinese guidelines have informed national guidelines for traditional
medicine use in COVID-19 in other countries such as Japan and
South Korea, which have fully or partially incorporated 3M3F.16-18 It is
critically important to independently review the evidence base behind
such claims considering such formally promotion in China and on inter-
national stages.
Whilst multiple reviews have reviewed the role of herbal
medicine—and CHM specifically—for COVID-19, none of them look at
3M3F specifically. Independent review is essential to shed light on the
debate around the effectiveness of CHM in the COVID-19 pandemic.
As such, our review is the first systematic review to evaluate whether
3M3F improves outcome in COVID-19 and test the specific efficacy
claims outlined above.
2 | METHODS
This rapid systematic review is reported following the PRISMA check-
list. We largely followed Cochrane Interim Rapid Reviews Guidance
produced specifically for the COVID-19 pandemic,19 except for tailor-
ing our search to Chinese bibliographic database. Our team included
bilingual authors experienced undertaking systematic review tasks in
English and Chinese and familiar with both health systems.
2.1 | Search strategy and selection criteria
In early May 2020, we searched PubMed, MEDLINE and CNKI (China
National Knowledge Infrastructure) databases with date restrictions
(2019–2020). We used keywords and MeSH terms in domains of
COVID (e.g., “COVID-19”, “Coronavirus”), Chinese and herbal medi-
cine (e.g., “Herbal medicine”, “Traditional Chinese Medicine”), official
terms for the 6 Medicines, (e.g., “Lianhua Qingwen”) and Chinese,
English and botanical terms for individual ingredients associated with
the 3 formulations (e.g., “Ma Huang”). Using the same or similar key-
words, we searched pre-print servers (MedRxiv and BioRxiv), clinical
trial registries (ChiCTR, Clinicaltrials.gov, WHO ICTRP, PROSPERO),
as well as Cochrane Task Exchange, Public Health England and a
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hand-search of references from selected articles. A detailed search
strategy and search term alternatives are available as supporting infor-
mation; see Supplementary material S1.
The search was repeated in September 2020. Web pages of Chi-
nese Center for Disease Control and Prevention,20 National Health
Commission of People's Republic of China21 and State Administration
of Traditional Chinese Medicine22 were searched for reference to clin-
ical studies. Studies identified from English (J. W., X. Y. H.) and Chi-
nese databases (Y. W., J. C.) were screened independently.
We included all Chinese- and English-language comparative stud-
ies of 3M3F, including randomized controlled trials (RCTs) or non-
randomized studies of interventions. We included any of the 3M3F
used separately or together, and alone or in conjunction with other
medicines. To be included, a study of any of the three formulations
had to report reasonable details of the formulation which were
consistent with guidelines from the State Administration of Tradi-
tional Chinese Medicine. We included any study on confirmed
COVID-19 patients, including those suspected initially and diag-
nosed retrospectively. We placed no limitation on age, disease
severity or ethnicity (in practice, most participants would have
been Chinese).
2.2 | Quality appraisal of studies
We used the version 2 of the Cochrane Risk of Bias for randomized
trials (RoB 2)23 and the Newcastle-Ottawa Scale for non-randomized
studies.24 One reviewer extracted data and critically appraised the
studies (Y. W., J. W.). A second reviewer double checked (reviewer 4,
reviewer 5). Disagreements were resolved by a third reviewer.
2.3 | Data extraction
Data were extracted by Y. W., reviewer 4, and reviewer 5. for Chi-
nese-language sources, and by J. W. and reviewer 4 for English-lan-
guage sources. We charted the following fields onto a data extraction
sheet: geographic location of recruitment, care setting, inclusion
criteria including participants' starting disease severity category, age,
gender, proportion of immuno-depression, pre-existing conditions,
and pregnancy status.
2.4 | Outcome measurements
We predefined a primary outcome domain (“change in disease sever-
ity category at the end of treatment”), since this was a major claim at
the government press conference. We sought clearly-defined catego-
ries (preferably from guidelines) and used clinically in the study
settings.
China standardized definitions of disease severity early in the
COVID-19 outbreak. The Chinese national guideline categorizes dis-
ease severity into mild, moderate, severe and critical; the Chinese
Center for Disease Control and Prevention has mild, severe and criti-
cal categories.25 This definition is cited in the US CDC guideline.26 In
other countries, “triage category” is used in regional or local
settings.27 Usually, these categorisations take many clinical character-
istics into consideration, including vital signs, symptoms, laboratory,
and radiographic findings. We did not include “disposition” (e.g., home
care or hospital admission) on its own as a marker of disease severity
unless the triage criteria were clearly stated. We included categories
“dead” and “cured” if the definition of “cured” was clear, and we did
not apply time limitations for disease progression or treatment. Only
categorisations from studies using the same definition were eligible
for meta-analysis.
We took an emergent approach to secondary outcomes, adjusting
our data extraction sheet to reflect outcomes reported in primary
studies. Although a disease severity category is already a composite
measure, we analysed changes in symptoms separately as secondary
outcomes, because of official claims that 3M3F could relieve symp-
toms. We extracted treatment outcomes of the symptoms reported in
COVID-19 patients.
At the time of this review, there was no international consensus
on the outcomes that should be reported when studying COVID-19,
so we extracted non-symptom outcomes if they were reported in the
primary studies; these included laboratory, radiology and healthcare
utilization measures. All these outcomes were mentioned in the press
conference.8
2.5 | Data analysis
When there were two or more studies reporting on the same outcome
measures, we conducted meta-analysis using RevMan [v5.4]. For con-
tinuous variables, because of variability in diagnostic and inclusion
criteria, interventions, and length of treatments and follow-up, a generic
inverse variance random effects model was utilized to pool the mean
difference (MD) with 95% confidence interval (CI) to incorporate het-
erogeneity.28 When the units of the outcome measures used across
studies were not consistent, the effects as standardized mean differ-
ences (SMD) were reported. For dichotomous variables, we com-
pared groups using risk ratio (RR) with 95% CI. Heterogeneity was
judged moderate when I2 > 30%, substantial when I2 > 50%, and
considerable when I2 > 75%.28 Potential sources were investigated
in a sensitivity analysis if appropriate when interpreting the findings.
3 | RESULTS
3.1 | Description of dataset
The study flowchart is shown in Figure 1. Thirteen studies - Six ran-
domized controlled trials and seven retrospective non-randomized
comparative studies covering a total of 1467 participants - met our
final inclusion criteria. All the studies were conducted in China: seven
in Wuhan, Hubei; one study29 in Qiandongnan, Guizhou; one30 in
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Beijing; one31 in Changsha, Hunan; one32 in Shiyan and one33 in
Xiangyang, Hubei; another one34 was a large scale of study recruiting
patients from 23 hospitals of nine provinces of mainland China. They
covered three Medicines (LHQW, JHQG and XBJ) and one formulation
(QFPD decoction). No relevant study was identified from China CDC,
NHC and SATCM's websites.
The key characteristics of the included studies are given in
Table 1. A table of excluded studies with reasons for exclusion is given
in the Supplementary material S2.
Eleven studies reference China's national guideline (fourth to sev-
enth revisions) to select study participants. The diagnosis criteria
evolved in these revisions. The fifth revision published in early
F IGURE 1 Study selection PRISMA flow chart







































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































6 WANG ET AL.
February allowed a clinical diagnosis for patients from high-risk areas
(Hubei Province) without laboratory confirmation, if chest imaging
was typical. This was later cancelled in the sixth revision. The seventh
revision published in early March added antibody test as an option of
laboratory tests. Two studies34,35 followed the fourth guideline to
select patients, one of which35 only involved suspected cases. These
suspected cases would be considered “clinically diagnosed” if the fifth
guideline criteria were applied. Eight studies followed fifth or sixth
guideline29,32,33,36-40 with confirmation of laboratory testing, and one
of them36 included a special inclusion requirement of being hospital-
ized for more than 6 days. One study39 recruited both suspected and
diagnosed cases according to the seventh treatment guideline,
and used epidemiological history, clinical symptoms, CT images and
etiological evidence as criteria. Two studies30,31 did not mention
guideline-based diagnosis. Two studies captured post-acute COVID
data,30,33 while none followed long enough to observe potential
chronic COVID symptoms. Eight studies30,35-37,40,41 provided a break-
down of participants' underlying conditions, most commonly hyper-
tension (ranging from 12.2% to 33.3%), coronary heart disease (2.1%–
16.2%), stroke (5.9%–15.9%), diabetes (7.8%–25.6%). Two studies39,41
reported a small number of patients with COPD (1.1%–4.9%). One
study41 included a small number of patients with pre-existing respira-
tory disease (chronic obstructive pulmonary disease and tuberculosis,
about 3%). Other small proportion of underlying condition reported
including chronic kidney and liver disease, cirrhosis, bronchial asthma,
hyperlipidaemia and diseases were not specified.
In all studies except one arm in Ref. 39, CHM were used in con-
junction with usual care (as recommended in the current version of
the Chinese national guideline), and compared with usual care alone.
“Usual care” in all the studies included three main approaches: nutri-
tion and supportive treatment, symptomatic treatment and antiviral
and antibacterial treatment.
3.2 | Quality appraisal of included studies
The results of quality appraisal of the included studies are shown in
Figure 2.
The quality assessment results of the RCTs are shown in Figure 2
(A). There were various forms of concerns for all six trails or they were
considered to be at high risk of bias. When evaluating the randomisa-
tion process, three trials34,39,41 produced random sequences through
SPSS or SAS software, whilst random number table was used in
another three trials.29,31,40 The allocation was concealed in two tri-
als34,41 concealed the allocation until the completion of enrolment.
Three studies29,31,40 did not report allocation concealment. One
study39 was designed as non-blind and patients were grouped
through a block random method, and this trial was assessed of high
risk in the randomisation process. Four trials34,39-41 were judged to be
at high risk of bias in outcome measurement, since assessors' and
patients' knowledge of highly promoted interventions could influence
assessment on outcomes, such as symptom improvement. The other
two RCT29,31 were open labelled as well. However, because their main
outcomes are derived from laboratory tests, they were judged to be
at low risk of bias. Three studies29,31,40 did not report whether
patients were aware of their allocation. Four studies29,31,39,41
reported no trial registration information on the manuscripts. More-
over, incapable of matching the studies with protocols retrieved from
Chinese Clinical Trial Registry, we judged them of some concerns with
the domain of “selection of reported result”. Only one study34 was
registered with the Number: Chi CTR-TRC-2000029434, but it30 did
not include intention-to-treat analysis which was considered as inap-
propriate to estimate the effect of assignment to intervention.
Of the non-randomized studies (all of which were retrospective
cohort studies), three studies35,36,38 were found to be of fair quality,
while the other four studies30,32,33,37 were of outstanding quality
(Figure 2(B)). There were extensive exclusion criteria for major dis-
eases (including renal disease, cancer and immunodeficiency) in all
studies, and comorbid respiratory diseases were excluded in all but
one study41 . Though the presence of these comorbidities is low for
Chinese COVID-19 patients, the population is likely to be representa-
tive of patients with COVID-19.42 The exposed and non-exposed
cohort were from the same community. Two studies35,38 failed to be
comparable on the basis of study design, and age or disease severity
of patients was normally controlled in other studies.30,32,33,36,37 All
the studies were completed, but only two were considered to be of
enough follow-up length: one study30 lasted for 25 days, and clearly-
recorded data of nucleic acid test and pneumonia recovery situation
were collected till the 15th day of hospitalization. Another one33
lasted for 22 days. The others five studies32,35-38 were finished within
7–10 days. Overall, medical records were performed in all studies
ascertain exposure and did not stipulate the outcome of interest was
not stipulated at the beginning of the studies, suggesting a potentially
significant source of bias.
3.3 | Effects of interventions on outcome
measures
The included trials featured four comparison groups: LHQW (plus
usual care) versus usual care (six studies); XBJ plus usual care versus
usual care (three studies); JHQG plus usual care versus usual care (two
studies), and QFPD plus usual care versus usual care (two studies)
(Table 1).
3.3.1 | Primary outcome
Our primary outcome measure (change in disease severity category
according to clinical guidelines) was adequately reported in only one
(non-randomized) study. One study36 reported that there was a signif-
icantly lower proportion of patients becoming severe in the treatment
group compared to the comparator group, as judged by a p value less
than 0.05 (see Table 2 for numbers). However, it was based on a small
sample size with very few events in some of the cells on the 2  2
table. Our own calculation of the data using Fisher exact test, which
WANG ET AL. 7
we believe to be appropriate given the distribution of the data,
showed a failure to meet statistical significance (p = 0.091) (see Sup-
plementary material S3).
One randomized controlled trial40 reported changes in disease
severity but we choose not to include these findings because the defi-
nition of category used as treatment outcome was not clear. There
was also inconsistency in the numbers presented in this study (see
Supplementary material S4). Moreover, the study included both mild
and moderate patients, but only presented data on progression to
severe or dead, missing progression from mild to moderate and pro-
gression to critical. We wrote to the corresponding author for clarifi-
cation, but received no response.
One retrospective analysis37 of QFPD decoction showed no sig-
nificant difference in the numbers of patients being cured (as defined
by the Chinese national guideline).
3.3.2 | Secondary outcomes
Improvement in symptoms
Primary studies measured symptom resolution differently. Fever reso-
lution, for example, was measured in three ways: time taken for fever
to resolve, whether fever was resolved after at the end of treatment,
and change in symptom score. Assigning a score to a symptom is a
common practice in CHM studies, although it has been criticized for
systematic errors, non-standardized use in each study and statistical
inappropriateness.43 As a result, we will not report on the Traditional
Chinese Medicine (TCM) scoring of symptoms, but have included
additional information in Supplementary material S5.
Figure 3(A-O) show the results of meta-analysis of studies which
tested the effectiveness of 3M3F on 13 reported COVID-19 symp-
toms. Limited findings suggested that 3M3F may reduce time of fever
recovery by SMD 0.98 days, 95% CI –1.78 to 0.17; partici-
pants = 163; studies = 3; I2 = 83%. There were larger proportion of
COVID-19 patients benefited from 3M3F in recovery of fever, cough,
fatigue/tiredness, phlegm, short of breath and muscle pain, but not in
the other seven symptoms reported (Table 2).
One RCT comparing LHQW granule as an add on to antiviral and
antimicrobial treatment in line with seventh edition of national guide-
lines failed to show a reduction in the proportion of patients with
improved fever RR 1.00 [0.91, 1.10], cough RR 0.86 [0.69, 1.06],
fatigue RR 1.05 [0.84, 1.33], diarrhoea RR 1.00 [0.80, 1.25], nausea/
vomiting RR 0.98 [0.75, 1.26], or loss in appetite RR 1.00 [0.80, 1.25],
comparing LHQW granule to usual care.39
F IGURE 2 Results of quality appraisal of primary studies
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Data from three retrospective cohort studies36-38 showed a sta-
tistically significant effect in favour of 3M3F in reducing time to fever
resolution by 0.98 days, 95% CI –1.78 to 0.17; participants = 163;
I2 = 83%) (Figure 3(A)). Three retrospective cohort studies35,36,38 and
a single RCT41 suggested larger proportion of patients with fever
resolved by taking LHQW (granule) and JHQG together with usual
care RR 1.38, 95% CI 1.19–1.61; participants= 318; I2 = 0%) (Figure 3
(B)).
There was large heterogeneity among studies reporting the pro-
portion of patients with cough resolved and they showed conflict
findings. Three retrospective cohort studies35,36,38 favoured LHQW
group RR 1.90, 95% CI 1.24–2.90; participants = 199; I2 = 18%, while
a RCT failed to prove the favourable effects of JHQG plus usual care
versus usual care RR 1.54, 95% CI 0.97–2.4541 (Figure 3(C)).
Similar positive findings from RCTs or retrospective cohort stud-
ies were observed in the proportion of patients with symptom resolu-
tion in fatigue/tiredness (RR 1.48, 95% CI 1.18–1.86;
participants = 219; studies = 3; I2 = 0%, Figure 3(D)), phlegm
(RR 1.97, 95% CI 1.08–3.61; participants = 176; studies = 4;
I2 = 52%, Figure 3(E)), shortness of breath (RR 3.93, 95% CI 1.89–
8.17; participants = 83; studies = 3; I2 = 0%, Figure 3(F)), and muscle
pain (RR 1.83, 95% CI 1.02–3.27; participants = 49; studies = 3;
I2 = 2%, Figure 3(G)). On the contrary, studies with small samples
failed to show a favourable effect over 3M3F in the resolution of
chest tightness (RR 2.00, 95% CI 0.81–4.96; participants = 89; stud-
ies = 3; I2 = 64%), diarrhoea (RR 1.09, 95% CI 0.65–1.82; partici-
pants = 35; studies = 3; I2 = 0%), nausea/vomiting (RR 1.25, 95% CI
0.82–1.90; participants = 43; studies = 3; I2 = 0%), loss in appetite
(RR 0.63, 95% CI 0.14–2.84; participants = 33; studies = 3;
I2 = 55%), sore throat (RR 1.35, 95% CI 0.68–2.70; participants = 26;
studies = 3; I2 = 0%), headache (RR 1.21, 95% CI 0.83–1.77; partici-
pants = 47; studies = 3; I2 = 0%), or block/running nose (RR 1.00,
95% CI 0.64–1.57; participants = 23; studies = 3; I2 = 0%).
Table 3 shows the impact on symptom resolution in studies which
were not amenable to meta-analysis. Statistically significant differ-
ences were shown for LHQW capsule (time to resolution of fever,
cough, and fatigue), LHQW granule (time to resolution of cough, short-
ness of breath, symptom scores for fever, dry and sore throat), and
QFPD decoction (time to resolution of cough).
Recovery or improvement of chest CT manifestations
Significant changes were shown in two retrospective cohort studies in
time to reduction in lung lesion on CT scan, in QFPD (decoction) -
4.80 days, 95% CI –5.82, 3.77, and JHQG (decoction) - 0.53 days,
95% CI –0.98, 0.08 at day 15, as adds on to usual care. In addition,
there was a larger proportion of patients experiencing recovery/
improvement of chest CT manifestations (RR 1.16, 95% CI 1.03–1.30;
participants = 521; 3 retrospective cohort studies; I2 = 0%, Fig-
ure 3(O)).
Other secondary outcome measure
Inconclusive findings on blood test results, length of hospital stay,
viral conversion, and medication used are reported narratively
(Table 4). One non-randomized study found statistically significant dif-
ferences in favour of LHQW in four laboratory tests (white cell count,
lymphocyte count, C-reactive protein and procalcitonin). The clinical
TABLE 2 Impact on symptoms: findings from meta-analysis (green represents that studies suggest a positive benefit; red represents that





(mean difference, 95% CI)
Proportion of patients with
symptom resolved - overall
3M3F (risk ratio, 95% CI)
Proportion of patients with
symptom resolved - LHQW
(risk ratio, 95% CI)
Proportion of patients with
symptom resolved - JHQG
(risk ratio, 95% CI)
Fever –0.98 days [1.78, 0.17] 1.38 [1.19. 1.61] 1.35 [1.14, 1.60] 1.51 [1.07, 2.14]
Cough — 1.74 [1.31, 2.30] 1.90 [1.24, 2.90] 1.54 [0.97, 2.45]
Fatigue/
tiredness
— 1.48 [1.18, 1.86] 1.51 [1.13, 2.00] 1.44 [0.98, 2.11]
Phlegm — 1.97 [1.08, 3.61] 2.46 [0.81, 7.51] 1.85 [1.01, 3.38]
Short of
breath
— 3.93 [1.89, 8.17] 3.93 [1.89, 8.17] —
Chest
tightness
— 2.00 [0.81, 4.96] 2.00 [0.81, 4.96] —
Diarrhoea — 1.09 [0.65, 1.82] 1.04 [0.42, 2.58] 1.11 [0.60, 2.07]
Nausea/
vomiting
— 1.25 [0.82, 1.90] 1.34 [0.59, 3.06] 1.17 [0.69, 1.99]
Loss in
appetite
— 0.63 [0.14, 2.84] .04 [0.42, 2.58] 0.06 [0.00, 1.03]
Sore throat — 1.35 [0.68, 2.70] 1.53 [0.38, 6.23] 1.30 [0.58, 2.87]
Headache — 1.21 [0.83, 1.77] 1.29 [0.67, 2.46] 1.17 [0.73, 1.87]




— 1.00 [0.64, 1.57] 0.90 [0.53, 1.53] 1.31 [0.57, 3.05]
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F IGURE 3 Forest plots of intervention studies where meta-analysis was possible (findings were interpreted separately)
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F IGURE 3 (Continued)
WANG ET AL. 11
F IGURE 3 (Continued)
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F IGURE 3 (Continued)
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F IGURE 3 (Continued)






























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































16 WANG ET AL.
significance of these results is not clear and the authors do not discuss
them. Inconclusive findings were observed in reduction in length of
stay: one small, non-randomized study37 showed a statistically signifi-
cant reduction in length of stay in those received QFPD decoction,
while one33 failed to show the same.
Adverse events
No study reported any serious adverse events (AE). Four studies did
not discuss AE in their results.33,36,38,39 Among those that discussed
AEs, three suggested no AE was observed either in the 3M3F or the
comparator groups29,31,35 and one reported no serious side effects.40
One RCT34 reported 45.8% (65/142) cases of AEs including abnormal
liver function, renal dysfunction, headache, nausea, vomiting, diar-
rhoea and loss of appetite in the add-on LHQW capsule, while the
control group reported 54.2% (77/142) cases with adverse events,
including abnormal liver function, renal dysfunction, headache, nau-
sea, vomiting, diarrhoea and loss of appetite. However, such compari-
son of this study34 was found with no statistical significance at 0.84,
95% CI 0.67–1.07. The RCT of41 using JHQG reported diarrhoea in
27 out of 82 (33%) participants in treatment group versus 0 in control
group, and this result has statistically significant difference.
4 | DISCUSSION
4.1 | Summary of key findings
Despite strong official endorsement of 3M3F to be effective for
COVID-19, the evidence base for this intervention rests on 13 studies
covering a total of 1467 participants. While the limited studies sug-
gest that 3M3F, when used on top of usual care, may offer some relief
for some symptoms and changes in lung lesion on CT scan experi-
enced by mostly mild or moderate COVID-19 patients, the results do
not support the high-level claims that 3M3F could prevent disease
from progressing to a more severe type. There were methodological
concerns in all studies, with especially high risk of bias in outcomes
assessment in the four RCTs. Missing and wrong protocol registration
information intensifies our concern over the integrity of these studies.
Of the six remedies making up 3M3F, four had been tested in any
experimental study that met our inclusion criteria. Our primary out-
come measure (reduction in severity of disease) did not achieve con-
vincing statistical significance in any of the primary studies. In relation
to the secondary outcomes, the positive effects of LHQW, JHQG, and
QFPD on various symptoms could be explained by bias in assessment
of outcome (and in particular, the widespread use of the “symptom
score” in TCM), and would need to be replicated before being viewed
as definitive. Similarly, the positive impacts of different 3M3F reme-
dies on radiological outcome (two studies), laboratory tests of bio-
markers (one study) and length of stay (two studies) need to be
replicated before being viewed as definitive.
With the exception of diarrhoea with JHQG, the 13 studies did
not report any adverse events linked to 3M3F use. Adverse events
have, however, been reported in the past when LHQW was used for
influenza.44,45 Previous studies have also reported some digestive sys-
tem side effects from using JHQG to treat influenza, though not signif-
icantly more than the control group.6 Duan and colleagues attributed
the high incidence of diarrhoea in their treatment group to the high
dose of JHQG they used to treat COVID-19, and also invoked classical
TCM theories to suggest that diarrhoea may have a curative role in
this condition.
Although we did not limit the publication language or geography,
unsurprisingly all included studies were conducted in China, thus the
findings may not be generalisable to other countries. During the edito-
rial process of this manuscript, we noticed a phase three trial of
LHQW in Singapore was registered, but the results were not posted
yet.46 There is also no placebo-controlled study, making it impossible
to assess the effect of 3M3F when used alone. Most of the articles
are of low quality and sample size, potentially limiting their use in info-
rming practice. We also observe some concerning practices in these
studies, for example, the number of trials registered in Clinical Trial
Registry is small, and in one case we cannot even find the registered
protocol using the protocol number given by the authors. Informed
consent was collected only verbally in some studies. However, it
should be recognized that these studies were often performed quickly
and opportunistically in the early acute phase of a sudden pandemic
without proper planning, and some limitations in study design and
execution are understandable. Moreover, these issues are not unique
to studies of 3M3F. There was a lack of core outcome set for clinic
trails of both Western medicine and traditional Chinese medicine dur-
ing in the early COVID-19 period, and this led to reporting inconsis-
tencies similar to what we saw in this review.47 However, given the
limitations of the studies published so far, the results of the studies do
not appear to definitively support the claim that 3M3F could prevent
the progression of COVID-19.
4.2 | Strengths and limitations of this review
To our knowledge, this is the first systematic review and meta-
analysis of a group of CHM specifically promoted for COVID-19.
Whilst some systematic reviews have examined the impact of
integrating any CHM with conventional treatment,48-50 our
review has expanded these findings by concentrating on more
specific aspects to avoid overgeneralisation. Firstly, comparing
with,48 we had examined the impact of 3M3F which was explic-
itly promoted for use in COVID-19, and till January 2021, our
review has identified all the published clinical studies using 3M3F
as interventions. Secondly, comparing with,49 we included both
RCTs and non-RCTs to provide more comprehensive information
to examine the work of 3M3F, because large-scale of RCTs are
insufficient in this field of research and data from other types of
studies also works as evidence. Thirdly, comparing with,49 we had
provided more accurate and detailed information in quality
appraisals of included studies and, comparing with,50 indepen-
dent analysis of outcomes of each intervention. We followed
Cochrane interim guidance for rapid reviews during this
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pandemic,19 and undertook independent statistical analysis of
key findings from primary studies.
One limitation is the small number of primary studies identified.
The relative success of China in managing the initial and second
waves of COVID-19 may have limited the ability to conduct trials
after detailed protocols based on early clinical experience had been
developed. It is also possible that the Chinese government had access
to additional unpublished data before developing its official statement
on 3M3F. At least 39 clinical trials for CHM interventions were regis-
tered in the Chinese Clinical Trials Registry by January 2021 before
this review was initiated, though it is unclear how many of these
relate to 3M3F.47 If such data exist, we recommend that they are
placed in the public domain, for example, by sharing and regularly
updating data under their registries, to ensure clinicians, researchers
and policy-makers are appropriately informed. Another limitation is
that other traditional medicines used for treatment of COVID-19
were not included in our review. We prioritized 3M3F as it has been
officially sanctioned and promoted by the Chinese government for
use in China and other foreign countries.
4.3 | Suggestions for further research
Larger, multi-centre randomized placebo-controlled trials of CHM,
and especially 3M3F, are urgently needed, with consistent inclusion
criteria and objective outcome measures designed to contribute to
meta-analyses. Better reporting of adverse events is needed to con-
firm the safety profile of 3M3F. It was beyond the scope of this
review to explore the pharmaceutical properties and alleged antiviral
mechanisms of the various ingredients; there is much scope for fur-
ther studies in this area, perhaps with a view to developing new
chemical entities for mainstream medicine. Many of these studies
were performed before much as known about the disease, or which
outcomes were most appropriate for inclusion. Only one study
attempted to measure or report viral load of COVID-19 patients or
whether this was reduced with the intervention; such variables should
be included in further research. Additionally, as our examination focused
primarily on the use of CHM in acute COVID-19 treatment, future
research examination of CHM for longer-term symptomatic relief may
be warranted given that many outcomes measured in the studies are also
often reported as significant in post-acute COVID-19.51
5 | CONCLUSIONS
The findings from this rapid systematic review neither support nor
refute the official claim that CHM (specifically 3M3F) alters the sever-
ity of COVID-19 or provides alleviation of symptoms. While the lim-
ited studies appear to suggest that 3M3F, when used on top of usual
care, may offer some relief for some symptoms experienced by mostly
mild or moderate COVID-19 patients, the results do not support the
high-level claims that 3M3F could prevent disease from progressing
to a more severe type. Studies were few in number, small in size, and
had significant methodological limitations (most notably, potential bias
in assessment of outcomes), though the positive nature of some indi-
vidual findings do suggest further examination may be warranted.
More rigorous multi-centre randomized placebo-controlled trials with
decent sample sizes are required to properly ascertain the potential
role of CHM in treatment of COVID-19.
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